Dimerix Ltd has released a press release.
Quarterly Appendix 4C and Activities Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Dimerix
- BioMarin to acquire Dimerix US Partner, Amicus Therapeutics
- DMX-200 ACTION3 Phase 3 trial completes recruitment
- Successful Completion of Planned IDMC Review
- Successful PARASOL Collaboration Data Analysis Outcome
- DMX-200 receives Orphan Drug Designation in Japan
Later from Dimerix
- Appendix 4D and Half Year Financial Report
- Dimerix Phase 3 Trial Last Patient Receives First Dose
- Dimerix to Conduct Review of ACTION3 Statistical Assumptions
- ACTION3 Statistical Review Complete
- Blinded assessment of ACTION3 statistical assumptions complete
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix